bioRxivCancer BiologyPreprint
mSWI/SNF interacts with the ribosome and its inhibition/mutations alter translation and sensitize to mTOR/PI3K inhibitors
L. Ulicna, S. C. Kimmey, C. M. Weber, G. M. Allard, S. C. Bendall, G. Crabtree, G. R. Bean, C. Van Rechem
Abstract
The chromatin remodelers mammalian SWItch/Sucrose Non-Fermentable (mSWI/SNF) subunits are mutated, deleted or amplified in more than 40% of cancers. Understanding their functions in normal cells and the consequences of cancers alterations will lead to path toward new targeted therapies. Canonically, mSWI/SNF complexes regulate the structure of chromatin, however they likely have additional functions which could be relevant in carcinogenesis. Here, we highlight the substantial alteration of mSWI/SNF subunits expression in both the nucleus and cytoplasm in breast cancer cases. We demonstrate mSWI/SNF cytoplasmic localization and interaction with the translation initiation machinery. Short-term inhibition and depletion of specific subunits alter protein synthesis, implicating a direct role for these factors in translation. Inhibition and depletion of specific subunits increase sensitivity to mTOR-PI3K inhibitors, suggesting a potential therapeutic opportunity for diseases harboring mutations in these complexes. Indeed, SMARCA4 pathogenic mutations decrease protein synthesis. Furthermore, taking advantage of the DepMap studies, we demonstrate cancer cells harboring mutations of specific mSWI/SNF subunits exhibit a genetic dependency on translation factors and are particularly sensitive to translation pathway inhibitors. In conclusion, we report an unexpected cytoplasmic role for mSWI/SNF in protein synthesis, suggesting potential new therapeutic opportunities for patients afflicted by cancers demonstrating alterations in its subunits. Statement of significanceThis study establishes direct functions for mSWI/SNF in protein synthesis. mSWI/SNF inhibition, depletion and cancer mutations alter translation and increase sensitivity to translation pathway inhibitors, illustrating the potential for new therapeutic strategies.
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A SWI/SNF-specific Ig-like domain, SWIFT, is a transcription factor binding platform
Siddhant U. Jain, Kaylyn E. Williamson, … Cigall Kadoch·SciencePeer-reviewed·Jan 1, 2026
- Integrated multiomic profiling reveals SWI/SNF subunit-specific pathway alterations and targetable vulnerabilities
Jorge Bretones Santamarina, Clémence Astier, … Annabelle Ballesta·bioRxiv·Jul 16, 2024
- Global Identification of Direct SWI/SNF Targets Reveals Compensation by EP400
Benjamin J. E. Martin, Eileen F. Ablondi, … Karen Adelman·bioRxiv·Mar 7, 2023
- In-Depth Characterization and Validation in BRG1-Mutant Lung Cancers Define Novel Catalytic Inhibitors of SWI/SNF Chromatin Remodeling
Z. Jagani, G. Chenail, … Haas·bioRxiv·Oct 22, 2019
- Inhibition of a Selective SWI/SNF Function Synergizes with ATR Inhibitors in Cancer Cell Killing
E. J. Chory, J. G. Kirkland, … G. J. Crabtree·bioRxiv·Jun 4, 2019
- Dose-dependent functions of SWI/SNF BAF in permitting and inhibiting cell proliferation in vivo
Aniek van der Vaart, Molly Godfrey, … Sander van den Heuvel·Science AdvancesPeer-reviewed·May 20, 2020